Our nanotherapeutic peptide micelles enable safe and effective drug and gene delivery by targeting disease sites and minimizing off-target side effects. By improving the performance of existing medications, our platform aims to enhance therapeutic outcomes and extend patient lifespans.
PAMs can be designed to target the cystic tissues in the kidneys specifically, reducing the drug dose needed and minimizing side effects.
Deliver therapeutic agents directly to the vascular lesions, potentially reducing plaque formation and inflammation.
The versatility of PAM design allows for the development of personalized therapies, tailoring the peptide sequence and payload to individual patient needs.
PAMs has shown to be safe in multiple mice models and pigs.
